Investment
Features
FeesSafety
Academy
More
Pluang+

Compare McKesson Corporation (MCK) vs Xpeng Inc - ADR (XPEV) Price & Performance

McKesson CorporationTrade
Xpeng Inc - ADRTrade

Price performance (Past 24H)

Key statistics

McKesson Corporation vs Xpeng Inc - ADR — how do they compare? McKesson Corporation trades at $878 (market cap $105.14B), while Xpeng Inc - ADR trades at $11.77 (market cap $11.15B). The key difference: McKesson Corporation is far larger — about 9.4× Xpeng Inc - ADR's market cap, and McKesson Corporation pays a 0.42% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.

MCKXPEV
Market Cap
$105.14B$11.15B
Sector
HealthConsumer Cyclical
52-Week High
$995.69$28.07
52-Week Low
$659.01$11.68
Enterprise Value
$111.67B$13.28B
Dividend Yield
0.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

McKesson Corporation

McKesson (MCK) trades at $877.87, down 0.23% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company reported robust Q1 2027 results with EPS of $9.93 beating estimates by 20% year-over-year, driven by specialty drug growth and oncology performance. Revenue reached $105.4 billion, up 8%, prompting management to raise full-year adjusted EPS guidance. Analyst consensus remains strongly bullish with 24 buy ratings and a $990.67 price target, representing 13% upside potential.

MCK presents a compelling investment case with consistent earnings beats, raised guidance, and strong operational cash flow of $6.9 billion projected for 2026. Key risks include margin pressure from the low 1.12% net income margin, high accounts payable of $55.33 billion, and negative shareholder equity of -$2.07 billion. The stock's valuation at 24.19 P/E appears reasonable given growth prospects, but investors should monitor debt levels and pharmaceutical pricing dynamics.

Xpeng Inc - ADR

XPeng (XPEV) trades at $11.74, down 2.17% today, with a bearish technical signal but oversold RSI. Revenue surged to $76.72B in 2025, yet net losses persist at -$1.14B. Recent news highlights July 2026 deliveries of 38,027 vehicles, up 4% YoY, and expansion into robotics and autonomous driving.

Outlook: Analyst consensus is bullish with a $17.00 price target, but risks include intense EV competition and ongoing profitability challenges. Upside hinges on new model success and global expansion, while cash flow volatility and high debt remain concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK

About Xpeng Inc - ADR

Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.

Read more on XPEV